New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
18:34 EDTEGHT, CLF, TRIP, JMBA, YELP, FB, HBI, KNDI, CRUS, ANGI, ARIA, LNKD, INFN, FTNT, TER, TIS, T, SPNC, TWTROn The Fly: After Hours Movers
UP AFTER EARNINGS: Fortinet (FTNT), up 7.8%... Hanesbrands (HBI), up 5.4%... 8x8 (EGHT), up 5.1%... Infinera (INFN), up 4.9%... Facebook (FB), reverses and is now trading up 5.1% following second quarter earnings conference call. NOTABLE: Twitter (TWTR), up 1.7%, LinkedIn (LNKD), up marginally, and Yelp (YELP), up 1.6% after Facebook reports second quarter results. ALSO HIGHER: Spectranetics (SPNC), up 7.1% after receiving FDA clearance for atherectomy products, Turbo-Tandem and Turbo Elite... Ariad Pharmaceuticals (ARIA), up 7.1%... Jamba (JMBA), up 3.8% after Engaged Capital reports stake in the company and announced that they had discussions with management. DOWN AFTER EARNINGS: AT&T (T), down 1.2%... Angie's List (ANGI), down 16.4%... Tripadvisor (TRIP), down 11.5%... Orchids Paper (TIS), down 7.4%... Cirrus Logic (CRUS), down 6.6%... Cliffs Natural (CLF), down 1.2%... Teradyne (TER), down 4%. ALSO LOWER: Kandi Technologies (KNDI), down 3.8% after being mentioned negatively in a Seeking Alpha blog post.
News For FTNT;HBI;EGHT;INFN;FB;TWTR;LNKD;YELP;SPNC;ARIA;JMBA;T;ANGI;TRIP;TIS;CRUS;CLF;TER;KNDI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
January 13, 2015
11:31 EDTCLFBofA/Merrill metals & steel analysts hold analyst/industry conference call
Subscribe for More Information
10:32 EDTCLFStocks with call strike movement; CLF FEYE
Subscribe for More Information
08:05 EDTJMBAJamba to appoint two new independent directors
Jamba announced that it has entered into an agreement to appoint James C. Pappas, Managing Member of JCP Investment Management, LLC, and Glenn W. Welling, Managing Member and Chief Investment Officer of Engaged Capital, LLC, to its Board of Directors, effective immediately, and that each will be included in Jamba’s slate of director nominees for election at the 2015 Annual Meeting of Stockholders. Jamba also agreed that one current member of the Board would not be re-nominated to stand for election at the 2015 Annual Meeting. With these changes, after the 2015 Annual Meeting the Jamba Board will comprise nine directors, eight of whom are independent. Under the terms of the agreement with Engaged Capital, LLC and certain of its affiliates, which beneficially own approximately 8.2% of the company’s outstanding shares, and JCP Investment Management, LLC and certain of its affiliates, which beneficially own approximately 2.3% of the company’s outstanding shares, JCP and Engaged Capital have agreed to vote their shares in favor of the election of the company’s slate of directors at the company’s 2015 Annual Meeting. In addition, JCP will, among other things, withdraw its nomination of candidates to stand for election at the company’s 2015 Annual Meeting and has agreed to customary standstill provisions through the date that is 45 days prior to the expiration of the company’s advance notice period for the nomination of directors at the company’s 2016 Annual Meeting of Stockholders.
07:40 EDTARIAARIAD reports net sales of Iclusig of approx. $55M for year ended Dec. 31
Subscribe for More Information
07:39 EDTARIAARIAD announces key strategic objectives for 2015
ARIAD Pharmaceuticals announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 2015 in San Francisco, California. These objectives are focused on expanded commercial, research and development, and new business development initiatives that together are expected to lead ARIAD to sustained profitability beginning in 2018 without the need for additional equity capital to fund its operations. ARIAD management will provide detail on its corporate strategy for the next several years. This new focus includes: Expanding the global commercial opportunity for Iclusig through a Japan/Asia partnership with Otsuka Pharmaceutical Co., Ltd., and additional regional distributorships, Leveraging its existing commercial infrastructure and investment, particularly in Europe, Securing a broad co-development and co-commercialization partnership for brigatinib, or AP26113, that will accelerate the study of brigatinib in earlier lines of treatment, Investing in three randomized clinical trials to evaluate Iclusig in earlier lines of treatment and potentially to expand its addressable market, Advancing its new development candidate, AP32788, into the clinic, and Achieving sustained profitability in 2018 by reaching global product revenue of more than $400M. Three key Iclusig clinical trials will begin in 2015 including a randomized, Phase 3 trial in patients with chronic-phase CML who have experienced failure after imatinib therapy. This second-line, global trial will evaluate two doses of Iclusig vs. the standard dose of nilotinib. The primary endpoint of the trial will be major molecular response by 12 months. The trial is expected to open to patient enrollment in the second half of 2015 and will be integral to potentially expanding Iclusig into earlier lines of treatment. We expect that approximately 500 patients will be enrolled in this trial. ARIAD says "In a major strategic shift for ARIAD, we expect to secure a broad partnership in 2015 to co-develop and co-commercialize brigatinib. In doing so, we will continue to leverage our existing infrastructure and capabilities, allowing us to accelerate the start of a randomized, first-line trial of brigatinib vs. crizotinib. A partnership will also provide for the exploration of new combination therapies in lung cancer that include brigatinib potentially with other approved and unapproved medicines." The company comments, "We expect to achieve profitability in 2018 through revenue growth and strategic partnerships over the next three years. This includes Iclusig revenue growth in the U.S. and in Europe, as well as Iclusig revenue from Japan and new geographies. We also anticipate increased cash flow from brigatinib revenue and partnership payments during this time period. We expect approval of Iclusig in Canada and Israel in 2015 and in Japan in 2016."
06:05 EDTSPNCOak Ridge Investments reports 5.67% passive stake in Spectranetics
Subscribe for More Information
January 12, 2015
17:29 EDTANGIAngie's List announces paid membership surpasses 3M
Angie's List announced that the company has surpassed 3M paid members, ending 2014 with 3,041,651 members subscribed to the national local services marketplace and consumer review site.
16:00 EDTTWTROptions Update; January 12, 2015
iPath S&P 500 VIX Short-Term Futures up 1.57 to 33.54. Option volume leaders: AAPL TSLA TWTR AMZN AA SIRI RIG FRO C according to Track Data.
15:43 EDTTWTRTwitter in talks to acquire ZipDial of India, TechCrunch reports
Subscribe for More Information
12:05 EDTANGIWeitz Investment reports 6.29% passive stake in Angie's List
Subscribe for More Information
11:48 EDTFBFacebook February volatility elevated at 39
Facebook January call option implied volatility is at 32, January weekly is at 29, February is at 39, March Is at 33; compared to its 26-week average of 34 according to Track Data, suggesting large near term price movement.
10:24 EDTFBFacebook, Xiaomi held talks over Facebook investment, Reuters says
Subscribe for More Information
10:12 EDTFBFacebook discussed potential investment in Xiaomi, Reuters reports
Subscribe for More Information
10:00 EDTTEROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTHBIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:34 EDTTWTRActive equity options trading
Subscribe for More Information
08:13 EDTHBIHanesbrands initiated with an Overweight at Morgan Stanley
Subscribe for More Information
07:26 EDTJMBAWedbush to hold a meetings at ICR XChange Conference
Subscribe for More Information
06:57 EDTTERTeradyne downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
06:06 EDTTSoftcard cuts 60 employees in restructuring, Re/code reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use